Steroid-sparing benefits of biologic use in hypereosinophilic syndrome and substantial disease burden across subtypes
All HES subtypes had a substantial disease burden and were commonly associated with fatigue, skin itch and pain. I-HES appeared to be more responsive to treatment than L-HES and M-HES. Biologic use for HES led to more patients experiencing clinical responses and was OCS-sparing.
Authors
- Jeremiah Hwee (ORCID: https://orcid.org/0000-0002-2623-7706)
- Lynn Huynh (ORCID: https://orcid.org/0000-0003-3110-6775)
- Rafael Alfonso‐Cristancho (ORCID: https://orcid.org/0000-0002-7060-5131)
- Mei Sheng Duh (ORCID: https://orcid.org/0000-0001-5035-6687)
- Marc E. Rothenberg (ORCID: https://orcid.org/0000-0001-9790-6332)
- Wilson da Costa
Institutions
- Cincinnati Children's Hospital Medical Center (US)
- GlaxoSmithKline (Canada) (CA)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Frontiers in Allergy
- Published
- 2025-05-23
- DOI
- https://doi.org/10.3389/falgy.2025.1605397
- Citations
- 1
- Primary Topic
- Eosinophilic Disorders and Syndromes
- Type
- article
- Field-Weighted Citation Impact
- 1.67